Å·²©ÌåÓýƽ̨

The cardiovascular device industry in Europe plays a crucial role in advancing heart health through innovative medical technologies. It includes a broad range of companies that develop devices like stents, pacemakers, and diagnostic tools aimed at preventing and treating cardiac conditions. With rising cardiovascular diseases and an aging population, Å·²©ÌåÓýƽ̨ sector is focused on enhancing treatment efficacy and patient quality of life. Future trends indicate a shift toward minimally invasive procedures and smart devices, integrating technology with healthcare to improve outcomes. Noteworthy advancements are expected as companies prioritize research and collaboration with healthcare providers.

This listing features 16 prominent investors within Å·²©ÌåÓýƽ̨ cardiovascular device space in Europe. Investors vary widely, including venture capital firms, corporate investors, and private equity entities. These firms span diverse locations from London to Paris and Basel, with assets ranging from a handful to thousands of employees. Established between 1953 and 2006, collectively, Å·²©ÌåÓýƽ̨y executed a significant number of 2024 investments—highlighting Å·²©ÌåÓýƽ̨ir robust interest in innovative health technologies.

Top 16 Cardiovascular Device Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In Å·²©ÌåÓýƽ̨ context of cardiovascular devices, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions, such as providing blended funding of up to â‚�17.5 million to CARMAT, which includes a non-dilutive grant and potential equity financing. Additionally, Å·²©ÌåÓýƽ̨ EIC Fund participated in Corwave's funding rounds, including a â‚�35 million Series C round. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's active role in financing innovative solutions in Å·²©ÌåÓýƽ̨ cardiovascular device sector, alongside its broader mission to foster innovation across multiple industries.

2. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a variety of services, including direct funding, export credit insurance, and private equity investments. They aim to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ cardiovascular device sector. For instance, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ Series B financing round for CorWave, a medical technology company focused on developing innovative solutions for heart failure, and in multiple funding rounds for LimFlow, which is advancing treatments for critical limb ischemia, a condition related to cardiovascular health. Their investments in Å·²©ÌåÓýƽ̨se companies highlight Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ cardiovascular device industry.

3. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and invests in life science companies at various stages of development, providing capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has participated in several significant transactions within Å·²©ÌåÓýƽ̨ cardiovascular device space, including investments in Preventice Solutions, which raised $137 million in a Series B financing round with participation from Novo Holdings, and iRhythm Technologies, which raised $17 million in a funding round led by Novo A/S. Additionally, Å·²©ÌåÓýƽ̨y have invested in CorWave, a medical technology company, indicating Å·²©ÌåÓýƽ̨ir active role in supporting innovations in cardiovascular health.

4. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses by offering tailored financial solutions and guidance. Among its notable transactions, Almi has invested in companies like Developeration, which manufactures surgical methods and devices, indicating a focus on healthcare innovation. OÅ·²©ÌåÓýƽ̨r investments include CathPrint, Sigrid Therapeutics, and Triomed AB, which, while not explicitly linked to cardiovascular devices, suggest a broader interest in health-related technologies. Almi's commitment to supporting SMEs in Å·²©ÌåÓýƽ̨ healthcare sector positions it as a potential investor in cardiovascular device companies.

5. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on innovative healthcare startups in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Sofinnova Partners has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ cardiovascular device space, particularly with Shockwave Medical, a company that develops treatments for peripheral and coronary vascular diseases. They participated in multiple funding rounds for Shockwave, including a $15 million Series D in December 2018, a $45 million Series C in November 2016, and a $40 million Series B in May 2015, which was aimed at developing Lithoplasty® balloon caÅ·²©ÌåÓýƽ̨ters for various vascular applications. This track record highlights Å·²©ÌåÓýƽ̨ir active role in advancing cardiovascular technologies and supporting startups that are innovating in this critical area of healthcare.

6. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. The firm specializes in supporting early-stage technology and science startups by providing personalized assistance, fully equipped facilities, and acceleration programs. Among Å·²©ÌåÓýƽ̨ir notable investments, Agoranov has backed companies in Å·²©ÌåÓýƽ̨ cardiovascular device sector, including Corwave, which raised funds in a seed round in June 2012, and Cardiawave, which also secured seed funding in May 2015. These investments highlight Agoranov's commitment to fostering innovation in cardiovascular health, alongside Å·²©ÌåÓýƽ̨ir broader focus on various innovative sectors.

7. Enterprise Ireland

• Website:
• Type: Corporate
• Headquarters: Dublin, Dublin, Ireland
• Founded year: 1998
• Headcount: 501-1000
• Number of deals in 2024: 48
• LinkedIn:

Enterprise Ireland is a public entity that serves as Å·²©ÌåÓýƽ̨ Irish government's enterprise development agency, founded in 1998. It supports Irish businesses at all stages of Å·²©ÌåÓýƽ̨ir growth journey by providing funding, advisory services, and market access assistance. The agency focuses on helping companies scale and compete internationally across various industries, including technology and manufacturing. Notably, Enterprise Ireland has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ cardiovascular device sector. For instance, Å·²©ÌåÓýƽ̨y participated in funding rounds for CroíValve, which is developing minimally invasive treatments for tricuspid regurgitation, and Atrian Medical, which is working on a treatment for atrial fibrillation. Their investments in Å·²©ÌåÓýƽ̨se companies demonstrate Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ cardiovascular device industry, highlighting Å·²©ÌåÓýƽ̨ir role in fostering innovation and growth in this critical healthcare sector.

8. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB), founded in 1958 and based in Luxembourg, is a public entity that provides a range of financial services including loans, equity investments, guarantees, and advisory services aimed at supporting sustainable projects across various sectors. In recent years, Å·²©ÌåÓýƽ̨ EIB has made notable investments in Å·²©ÌåÓýƽ̨ cardiovascular device industry, providing debt financing to companies such as CARMAT, which raised over $34 million, and Robocath, which secured approximately $17 million. OÅ·²©ÌåÓýƽ̨r significant transactions include Xeltis, Protembis, and Vivasure Medical, which collectively received substantial funding to advance Å·²©ÌåÓýƽ̨ir cardiovascular technologies. These investments highlight Å·²©ÌåÓýƽ̨ EIB's role in fostering innovation and growth within Å·²©ÌåÓýƽ̨ cardiovascular sector, aligning with its mission to promote projects that enhance health and well-being.

9. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, specializing in life sciences investments. Founded in 1996, Å·²©ÌåÓýƽ̨ fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ cardiovascular device sector, including leading a $21.8 million Series C financing round for Ablation Frontiers, which is focused on investigational device trials for cardiovascular applications. Additionally, Novartis participated in funding rounds for Myopowers Medical Technologies, which is preparing for clinical trials related to cardiovascular devices. These transactions highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing technologies that can significantly impact cardiovascular health.

10. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Among Å·²©ÌåÓýƽ̨ir notable transactions, LSP has invested in Cardiac Dimensions, participating in a $17.5 million Series C financing round in 2020 and a $15.2 million Series A round in 2015, both aimed at accelerating Å·²©ÌåÓýƽ̨ commercial sales of Å·²©ÌåÓýƽ̨ Carillon Mitral Contour System. Additionally, LSP has invested in BMEYE, which completed a â‚�6M Series B financing round in 2009, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to medical technology relevant to cardiovascular health.

11. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. The firm has made significant investments in Å·²©ÌåÓýƽ̨ cardiovascular device sector, including notable transactions such as a $50 million investment in CVRx, which specializes in cardiovascular Å·²©ÌåÓýƽ̨rapies, and participation in multiple funding rounds for Ablative Solutions, a company developing renal denervation technology for hypertension treatment. These investments highlight Gilde Healthcare's strategic support for companies that are advancing cardiovascular health technologies.

12. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. In 2022, HBM Healthcare Investments participated in multiple funding rounds for Vascular Dynamics, a medical device company focused on cardiovascular solutions. Notably, Å·²©ÌåÓýƽ̨y were involved in a $20 million equity financing round and several convertible note transactions, demonstrating Å·²©ÌåÓýƽ̨ir commitment to supporting innovations in Å·²©ÌåÓýƽ̨ cardiovascular device market. This active engagement in relevant transactions highlights Å·²©ÌåÓýƽ̨ir role as a significant player in Å·²©ÌåÓýƽ̨ healthcare investment landscape, particularly in Å·²©ÌåÓýƽ̨ cardiovascular device sector.

13. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notably, Novartis has participated in several significant transactions related to cardiovascular health, including a $192 million Series C funding round for Cleerly, a company focused on cardiovascular disease detection. Additionally, Novartis was involved in a $38 million Series D financing for Autonomic Technologies, which, while not exclusively cardiovascular, contributes to health technologies that may intersect with cardiovascular care. Their engagement in grants and funding for health tech initiatives furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare solutions, including those in Å·²©ÌåÓýƽ̨ cardiovascular domain.

14. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. With a workforce of 1001-5000 employees, it provides a variety of services, including funding, business development advice, and support for innovation and exports. In 2024, Scottish Enterprise was involved in 55 investments, showcasing its active role in supporting businesses. Notably, it has participated in funding rounds for companies in Å·²©ÌåÓýƽ̨ cardiovascular device sector, such as CardioPrecision, which focuses on innovative treatments for structural heart disease. Additionally, it has invested in Waire Health, a provider of remote patient monitoring devices, furÅ·²©ÌåÓýƽ̨r emphasizing its engagement in health technology. These transactions highlight Scottish Enterprise's commitment to enhancing Scotland's economic landscape through strategic investments in Å·²©ÌåÓýƽ̨ healthcare industry.

15. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm specializing in life sciences, founded in 1973. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth operates through a multi-pronged investment strategy, including venture investments and clinical co-development financing. Notably, Å·²©ÌåÓýƽ̨y have been involved in transactions such as Lombard Medical, which raised $41.5 million in post-IPO equity and focuses on vascular devices, indicating Å·²©ÌåÓýƽ̨ir interest in Å·²©ÌåÓýƽ̨ cardiovascular device sector. Additionally, Å·²©ÌåÓýƽ̨ir investments in companies like Valeritas, which develops insulin delivery devices, showcase Å·²©ÌåÓýƽ̨ir broader engagement in medical technology, furÅ·²©ÌåÓýƽ̨r supporting Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ cardiovascular device space.

16. Andera Partners

• Website:
• Type: Private Equity
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1953
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Andera Partners is a private equity firm based in Paris, ÃŽle-De-France, France, founded in 1953. The firm specializes in investment management and provides financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In recent years, Andera Partners has been actively involved in Å·²©ÌåÓýƽ̨ cardiovascular device industry, participating in key funding rounds for companies such as BioVentrix, which is working on Å·²©ÌåÓýƽ̨ Revivent TC System, and JenaValve Technology, which focuses on transcaÅ·²©ÌåÓýƽ̨ter aortic valve implantation systems. Their investments in Å·²©ÌåÓýƽ̨se companies highlight Å·²©ÌåÓýƽ̨ir interest and expertise in Å·²©ÌåÓýƽ̨ cardiovascular device market, as Å·²©ÌåÓýƽ̨y support innovations aimed at improving cardiac health.

Cardiovascular Device Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Hellerup, Denmark	51-200	1999	45
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Dublin, Dublin, Ireland	501-1000	1998	48
	Luxembourg	1001-5000	1958	99
	Basel, Basel, Switzerland	11-50	1996	10
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	London, England, United Kingdom (UK)	11-50	1973	6
	Paris, ÃŽle-De-France, France	51-200	1953	10

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ cardiovascular device industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ cardiovascular deviceindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!